Strategic Development


ISIS Pharmaceuticals Inc.

in
 
ISIS Pharmaceuticals Inc. announced that Bristol-Myers Squibb Company has selected a compound from the companies' collaboration as a development candidate. As a result,Isis will receive a $2 million milestone payment.

PDL BioPharma Inc

in
#1  PDL BioPharma Inc. said it will stop pursuing the sale of the company or its biotechnology assets after a firm offer failed to emerge, sending its shares down nearly 19% in extended trading. The company said it now plans to cut 260 jobs and restructure to focus on discovery and development of antibody-based drugs.

Genzyme Corp.

in
Genzyme Corp. announced the U.S. launch of the phosphate binder Renvela(R) (sevelamer carbonate) for dialysis patients, as well as significant progress in its international efforts to secure additional approvals for the product. Genzyme has submitted a marketing authorization application to the European Medicines Agency seeking approval of Renvela for the control of serum phosphorus in chronic kidney disease patients regardless of whether they are on dialysis.

Fresenius Medical Care AG & Co. KGAA

in
Fresenius Medical Care AG & Co. KGAA is expanding the capacity for producing dialysis products at its plant in St. Wendel, Germany. The Company will invest a total of approximately EUR 39 million over the next 12 months. About EUR 23 million will be invested in an additional building and two new spinning lines for hollow fibers, the key component of dialyzers (artificial kidneys).

Shares in Shire plc rose by almost 10%

in
Shares in Shire plc rose by almost 10%, as traders reported talk of bid interest from Pfizer. Shire declined to comment. Shire has seen as a bid target, because of its strong portfolio of recently-launched drugs. Pfizer has been trying to come up with a plan to offset competition to its $12 billion-a-year cholesterol fighter Lipitor.

Para Membranes has entered into an exclusive strategic distribution

in
Para Membranes has entered into an exclusive strategic distribution relationship with PRISMEDICAL Corporation for sales of Para Membranes' patented HFM products.
 

Gambro AB

in
Gambro AB announced the start of a strategic alliance with Sandoz, Inc. Both companies have agreed to cooperate in the launch of Sandoz' biosimilar Binocrit, the first biosimilar epoetin alfa which has been approved by the European Commission in August this year.

Renal Solutions

in
US company Renal Solutions has selected Sabic Innovative Plastics’ improved haemo-compatibility Lexan HPM grade of polycarbonate to produce its Pulsar blood pump, which lies at the core of its Allient Sorbent Haemodialysis System. More.

Dubai International Capital

in
Dubai International Capital (DIC) and private-equity firm Bridgepoint plan to bid jointly for healthcare group Euromedic International for about 700 million pounds ($1.4 billion), the London Times said on Sunday. More.
 

Isotechnika Inc

in
Isotechnika Inc. announced that the International Nonproprietary Name (INN) expert committee has accepted the proposed generic name of its lead immunosuppressive drug, ISA247. ISA247 will now be referred to as voclosporin. The name will serve to identify the active pharmaceutical substance during the drugs' life-time worldwide.

12345678next ›last »
Syndicate content